' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
Lagler, FB; Gersting, SW; Zsifkovits, C; Steinbacher, A; Eichinger, A; Danecka, MK; Staudigl, M; Fingerhut, R; Glossmann, H; Muntau, AC;
Biochem Pharmacol. 2010; 80(10): 1563-1571.
Originalarbeiten (Zeitschrift)


Lagler Florian


Patients with malignancies are considered to be at increased risk of acquiring influenza. Because of higher complication and case fatality rates, preventive measures such as vaccination are of great interest. The objective of this study was to assess the acceptability, tolerability and immunogenicity of an adjuvant-free whole-virion pandemic influenza A (H1N1) vaccine in cancer patients with ongoing anticancer treatment during a "pandemic situation". Adult patients with hematologic malignancies or solid tumors and concurrent cytotoxic, targeted, and/or hormone therapy were recruited during the influenza A (H1N1) pandemic in 2009/2010 and were offered free vaccine. Antibody titers were measured using virus-specific hemagglutination inhibition assay and ELISA. Among 285 patients with solid tumors who were offered vaccination during their therapy, 260 (91.2%) declined and 25 (8.8%) accepted. Seventeen patients with hematologic malignancies were also vaccinated during therapy; 23 healthy individuals served as a control group. When measured using hemagglutination-inhibition assays, rates of seroprotection, seroconversion, and geometric mean titer ratios after the second vaccination were 96%, 70%, and 4.1 respectively among the healthy individuals, 90%, 52%, and 4.3 among patients with solid tumors, and 67%, 13%, and 1.5 among patients with hematologic malignancies during therapy (P<0.05). When measured using ELISA, seropositivity differed significantly among the three groups after the second vaccination: healthy individuals 74%, patients with solid tumors 57%, those with hematologic malignancies 13% (P<0.001). The vaccine was well tolerated. Our results demonstrate a low uptake of the well tolerated adjuvant-free influenza A (H1N1) vaccine by cancer patients receiving anticancer treatment during the pandemic of 2009/2010. Among the vaccinated patients, the immune response was weaker than that in healthy individuals. The immune response in patients with hematological malignancies was low. Two doses of vaccine are needed in these immunosuppressed patients. Copyright © 2012 Elsevier Ltd. All rights reserved.

Useful keywords (using NLM MeSH Indexing)





Biopterin/therapeutic use

Breath Tests

Disease Models, Animal

Dose-Response Relationship, Drug



Mice, Mutant Strains



Phenylalanine Hydroxylase/deficiency*

Phenylalanine Hydroxylase/genetics


Phenylketonurias/drug therapy*



Treatment Outcome


Find related publications in this database (Keywords)

Mouse model
Compound heterozygous